- Home
- SLSR vs STOK Comparison
SLSR vs STOK Comparison
Compare SLSR & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLSR
- STOK
- Stock Information
- Founded
- SLSR 2018
- STOK 2014
- Country
- SLSR Switzerland
- STOK United States
- Employees
- SLSR N/A
- STOK N/A
- Industry
- SLSR
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- SLSR
- STOK Health Care
- Exchange
- SLSR NYSE
- STOK Nasdaq
- Market Cap
- SLSR 539.0M
- STOK 638.8M
- IPO Year
- SLSR N/A
- STOK 2019
- Fundamental
- Price
- SLSR $5.77
- STOK $11.69
- Analyst Decision
- SLSR Buy
- STOK Strong Buy
- Analyst Count
- SLSR 2
- STOK 5
- Target Price
- SLSR $11.00
- STOK $24.50
- AVG Volume (30 Days)
- SLSR 41.9K
- STOK 530.5K
- Earning Date
- SLSR 08-08-2025
- STOK 08-06-2025
- Dividend Yield
- SLSR N/A
- STOK N/A
- EPS Growth
- SLSR N/A
- STOK N/A
- EPS
- SLSR N/A
- STOK 0.88
- Revenue
- SLSR N/A
- STOK $190,908,000.00
- Revenue This Year
- SLSR N/A
- STOK $378.84
- Revenue Next Year
- SLSR N/A
- STOK N/A
- P/E Ratio
- SLSR N/A
- STOK $13.34
- Revenue Growth
- SLSR N/A
- STOK 2333.81
- 52 Week Low
- SLSR $1.90
- STOK $5.35
- 52 Week High
- SLSR $5.75
- STOK $16.15
- Technical
- Relative Strength Index (RSI)
- SLSR 79.23
- STOK 61.39
- Support Level
- SLSR $4.51
- STOK $11.19
- Resistance Level
- SLSR $4.72
- STOK $12.00
- Average True Range (ATR)
- SLSR 0.23
- STOK 0.53
- MACD
- SLSR 0.09
- STOK -0.09
- Stochastic Oscillator
- SLSR 99.34
- STOK 48.15
About SLSR SOLARIS RESOURCES INC
Solaris Resources Inc is advancing a portfolio of copper and gold assets in the Americas, which includes a high-grade resource with expansion and additional discovery potential at the Warintza copper and gold project in Ecuador; discovery potential on the grass-roots Tamarugo project in Chile and Capricho and Paco Orco projects in Peru, and the La Verde joint venture project.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.